Market research
ALINT.PA IntegraGen SA
PA EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 1M
- P/E ratio
- Not available
- Analyst target
- 3.9
- Dividend yield
- Not available
- Beta
- 0.34
Profile
Company facts
- Exchange
- PA
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- FR0010908723
- Market cap
- 1M
- P/E ratio
- Not available
- Analyst target
- 3.9
- Dividend yield
- Not available
- Beta
- 0.34
About
About IntegraGen SA
IntegraGen SA provides researchers with sequencing solutions, data management tools, and biostatistical, and bioinformatics support services in France. The company's genomic pharma services DNA sequencing for oncology and rare disease research; and NGS testing for cancer research. It also provides MERCURY, an online biological interpretation tool for oncology intended to assist pathologists and oncologists in transforming raw data obtained through high-throughput sequencing into a molecular report for translational and clinical research use; Galileo, a cloud-based app for dynamic exporation of RNA-Seq expression data; and GeCo, a genomic consulting service that offers researchers with access to biostatistics and bioanalytics experts. IntegraGen SA was incorporated in 2000 and is headquartered in Évry, France. IntegraGen SA operates as a subsidiary of OncoDNA SA.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ALINT.PA discussion.
5 years, 5 months ago
IntegraGen SA is currently in a long term downtrend where the price is trading 26.7% below its 200 day moving average.
From a valuation standpoint, the stock is 99.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.5.
Based on the above factors, IntegraGen SA gets an overall score of 1/5.